Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-0554
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-07-24T06:09:04.958550Z
status: published
lens: g_space
sector: health
headline: Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma
dek: While survival outcomes in multiple myeloma (MM) have improved with contemporary combination therapies, predicting disease trajectories for individual patients at diagnosis remains a significant challenge. We investigate the prognostic value of a noninvasive biomarker-cell-free DNA (cfDNA)‑derived 5-hydroxymethylcytosine (5hmC) signature-in newly diagnosed MM, aiming to improve risk stratification at diagnosis. In this prospective cohort study, 321 patients with newly diagnosed MM were enrolled between 2010 and…
gain_title: A machine-learning derived weighted score from 18 cfDNA 5hmC-modified genes at diagnosis predicted overall and progression-free survival in newly diagnosed multiple myeloma after adjusting for stage and other clinical factors.
problem_title: (none)
trace_subject: (none)
gain_reading: A machine-learning derived weighted score from 18 cfDNA 5hmC-modified genes at diagnosis predicted overall and progression-free survival in newly diagnosed multiple myeloma after adjusting for stage and other clinical factors.
gain_evidence: cfDNA-derived 5hmC signatures at diagnosis provide independent prognostic information for OS and PFS in MM
problem_reading: (none)
problem_evidence: (none)
quick_read: In a prospective study of 321 patients with newly diagnosed multiple myeloma enrolled between 2010 and 2017, investigators measured 5-hydroxymethylcytosine modifications in cell-free DNA collected at diagnosis and built an 18-gene weighted prognostic score using elastic net Cox modeling and machine learning.

The score provided independent prognostic information for overall survival and progression-free survival in a validation set, which matters for noninvasive risk stratification at diagnosis, but the authors note that independent validation in contemporary treatment settings is still required before clinical adoption.
limitation: Findings are from a single prospective cohort enrolled 2010-2017 and authors state further independent validation is needed before clinical use within contemporary risk stratification.
tag: Evidence-backed gain
key_points: Prospective cohort of 321 newly diagnosed multiple myeloma patients enrolled 2010-2017 with follow-up through 2022 and median follow-up 70.5 months. | Genome-wide 5hmC modifications in gene bodies were profiled from cfDNA collected at diagnosis and compared to bone marrow-derived tumor cells. | Elastic net regularization with Cox model identified 18 key genes to build a weighted prognostic score validated in a held-out validation set. | During follow-up 127 deaths occurred and the score remained associated with OS and PFS at 24-, 48-, and 72-month follow-up periods.
rundown: Researchers profiled genome-wide 5hmC in cfDNA at diagnosis from 321 newly diagnosed MM patients and used elastic net regularized Cox modeling to select 18 genes for a weighted prognostic score.

In validation, the score was independently associated with overall survival and progression-free survival after controlling for stage, LDH and treatment type, and associations persisted at 24, 48 and 72 months.
sources:
- peer_reviewed | JCO Precision Oncology | https://doi.org/10.1200/po-25-01121 | 2026-07-23
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

2c2f4e8f352dce65ab429a69b8c1be226f9af3663674cb49e029b75f300ff51d

previous

0000000000000000000000000000000000000000000000000000000000000000